EleniEfstathiouMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Efstathiou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Efstathiou's full profile

Already have an account?

Office
1515 Holcombe Blvd

Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of AthensClass of 1998

Certifications & Licensure

TX State Medical License 2019 - 2024
OK State Medical License 2020 - 2021

Clinical Trials

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer Start of enrollment: 2015 Oct 29
Completed
Phase 2
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Start of enrollment: 2017 Oct 13
Completed
Phase 2
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Mar 06
ACTIVE_NOT_RECRUITING
PHASE2
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Start of enrollment: 2020 Nov 24
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Pati...
Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, Nakul Gupta, Shu Zhang
The Prostate. 2025-04-01
7 citations
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2025-02-01
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel...
Michalis Liontos, Anna Goussia, Nikolaos Korfiatis, Kyriaki Papadopoulou, Georgios Kanellis
Clinical Genitourinary Cancer. 2025-02-01

Lectures

A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naÃ¯ve prostate cancer (M0...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

M0 CPRC: Overview of Treatment Options APCCC 2022 Presentation Eleni EfstathiouAugust 2022

Press Mentions

Niraparib and Abiraterone Combination Is Beneficial in Prostate CancerMarch 20th, 2023
Latest in Hormone Sensitive Prostate CancerFebruary 18th, 2023
Niraparib Improves rPFS in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerFebruary 17th, 2023
Join now to see all